Ceftobiprole

• Description :

  Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia[1][2][3].

• Product Name Alternative :

  Ro 63-9141; BAL 9141

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Antibiotic; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Ceftobiprole.html

• Purity :

  97.22

• Solubility :

  DMSO : 4.95 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C(N12)=C(/C=C3C(N([C@H]4CNCC4)CC/3)=O)CS[C@]2([H])[C@H](NC(/C(C5=NSC(N)=N5)=N\O)=O)C1=O)O

• Molecular Formula :

  C20H22N8O6S2

• Molecular Weight :

  534.57

• Precautions :

  H302, H312, H332

• References & Citations :

  Staphylococcus aureusStaphylococcus aureus

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  β-lactam

• CAS Number :

  [209467-52-7]